Cognitive impairment in schizophrenia: how experimental models using nonhuman primates may assist improved drug therapy for negative symptoms.
Antipsychotic drugs provide effective relief from hallucinations but do not improve, and may even induce, other symptoms of schizophrenia. Tardive dyskinesia, which is often associated with intellectual impairment, is generally attributed to chronic therapy with antipsychotic drugs. However, the possible contribution of medication to cognitive impairment is not easily dissociated from the underlying progression of the disease. Recently evidence has accumulated from studies performed in patients and experimental monkeys that augmentation of catecholamine function may improve performance on certain cognitive tasks. Further investigation of the role of catecholamines in cognition is warranted in order to assist development of antipsychotic drugs with fewer undesirable effects and entirely new approaches to therapy for cognitive impairment in schizophrenia.
Rupniak
N M
NM
Merck Sharp & Dohme, Neuroscience Research Centre, Harlow, Essex, U.K.
Iversen
S D
SD
D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology*; D004195:Disease Models, Animal; D006801:Humans; D011323:Primates; D012559:Schizophrenia / Q000150:complications* / Q000188:drug therapy*
D014150:Antipsychotic Agents